Vanflyta is a brand name for a medication prescribed for certain types of acute myeloid leukemia (AML). Contacting a healthcare provider is the primary way to obtain information or prescriptions for Vanflyta [1].
What is Vanflyta used for?
Vanflyta, in combination with azacitidine, is approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ≥75 years of age or ineligible for intensive induction chemotherapy [1]. AML is a type of cancer that affects blood and bone marrow [2].
How does Vanflyta work?
Vanflyta is a FLT3 inhibitor. It works by blocking the activity of a protein called FLT3, which is a type of receptor tyrosine kinase. In some cases of AML, mutations in the FLT3 gene lead to an overactive FLT3 protein, which can promote the growth and survival of leukemia cells. By inhibiting FLT3, Vanflyta can help to slow or stop the growth of these cancer cells [1].
What are the side effects of Vanflyta?
Common side effects of Vanflyta, when used with azacitidine, can include low blood cell counts (neutropenia, thrombocytopenia, anemia), muscle and bone pain, nausea, vomiting, diarrhea, and fatigue [1]. It is important to discuss potential side effects with a healthcare professional.
How can I get a prescription for Vanflyta?
Prescriptions for Vanflyta are issued by licensed healthcare providers, such as oncologists or hematologists, who determine if the medication is appropriate for a patient's specific condition [1].
Where can I find information on Vanflyta patents?
Information regarding patents for Vanflyta and its active pharmaceutical ingredient can be found through patent databases. DrugPatentWatch.com offers resources and data on drug patents, which may include details on Vanflyta's patent status [3].
What is the difference between Vanflyta and other AML treatments?
Vanflyta is a targeted therapy that specifically inhibits FLT3, a common mutation in AML. Other AML treatments include chemotherapy, stem cell transplantation, and other targeted therapies that may target different mutations or pathways involved in AML [2]. The choice of treatment depends on factors such as the patient's age, overall health, and specific genetic mutations in their leukemia cells.
When does Vanflyta's patent expire?
Patent expiry dates for specific medications can vary and are often complex, involving multiple patents covering different aspects of the drug. Information on patent durations and potential expiry can be researched through patent tracking services like DrugPatentWatch.com [3].
---
* [1] https://www.vanflyta.com/
* [2] https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
* [3] https://drugpatentwatch.com/